New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...
A simple change in how primary care clinics approach weight management is delivering big public health wins. PATHWEIGH lets ...
Many people who use these medications don’t want to stay on them long term. But research has repeatedly shown that quitting ...
Nutra, the science-driven company behind ProLon, explain why chronic calorie restriction often backfires — and how time-bound ...
The appetite for weight-loss drugs, known as glp-1 agonists, has been insatiable since they hit the market a decade ago. In 2024 global spending on them reached $54bn, a figure that is sure to rise in ...
Here's how to get started.
"I'm a whole new person." Read Molly's inspiring success story about ESG, a minimally invasive weight loss solution from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results